One of the most important questions in obesity medicine is whether losing weight with newer medications translates into better long-term cardiovascular health. An August 2026 analysis of three-year SURMOUNT-1 data provides encouraging evidence for tirzepatide – but the distinction between predicted risk and actual cardiovascular events is essential. What researchers studied SURMOUNT-1 was a randomized
When patients start tirzepatide (Zepbound) for obesity, the number on the scale is usually the most visible outcome. But obesity treatment is ultimately about health, not simply weight. A newly published analysis from the SURMOUNT clinical-trial program asks a useful question: how often do patients improve several important cardiometabolic measures at the same time? What
1. Orforglipron after Wegovy or Zepbound. ATTAIN-MAINTAIN found that patients transitioned from tirzepatide or semaglutide to oral orforglipron (Foundayo) maintained substantially more of their prior weight reduction than patients switched to placebo. A new option in the maintenance discussion. https://belite.com/orforglipron-maintenance-after-wegovy-zepbound/ 2. CagriSema vs. Zepbound. CagriSema delivered 23% average weight loss in its head-to-head trial —
Foundayo (orforglipron) brings GLP-1 obesity treatment into a once-daily pill with no food or water restrictions — changing how some patients approach initiation and maintenance therapy.
CagriSema produced 20%+ average weight loss versus placebo — but in the REDEFINE 4 head-to-head it did not prove non-inferior to tirzepatide. Here is what both results mean.
ATTAIN-MAINTAIN found that patients switched from tirzepatide or semaglutide to oral orforglipron preserved substantially more prior weight loss than those switched to placebo.
